Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333515 | PMC |
| http://dx.doi.org/10.1200/JCO-25-00452 | DOI Listing |
Publication Analysis
Top Keywords
erratum first-line
4
first-line nivolumab
4
nivolumab relatlimab
4
relatlimab versus
4
versus nivolumab
4
nivolumab ipilimumab
4
ipilimumab advanced
4
advanced melanoma
4
melanoma indirect
4
indirect treatment
4
Similar Publications
Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy.
Pharmacoecon Open
August 2025
Takeda Italy S.p.A., Rome, Italy.
Corrigendum to "First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence" [Crit. Rev. Oncol./Hematol. 206 (2025) 104555].
Crit Rev Oncol Hematol
September 2025
Texas Oncology, US Oncology Network, The Woodlands, TX, USA.
Corrigendum to "From "contraindicated" to "first line" - Current mechanistic insights beyond canonical β-receptor signaling" [COPHAR 76 (2024) 102458].
Curr Opin Pharmacol
July 2025
Institute of Pharmacology and Toxicology, University of Würzburg, Germany; Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Cardiovascular Pharmacology, Dortmund, Germany. Electronic address: